Cellenion

Cellenion

Lyon, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.2M

Overview

Cellenion is a specialized provider of high-precision instrumentation for single-cell isolation and 3D cellular model handling, addressing critical needs in advanced life science research and drug discovery. Its core technology, the cellenONE® platform, enables gentle, image-based dispensing of individual cells and is complemented by the upcoming spheroONE® system for organoids and spheroids. The company operates on a product and consumables business model, supported by contract services, and is positioned at the intersection of the rapidly growing single-cell analysis and complex 3D model markets. Backed by the manufacturing and innovation heritage of its parent company SCIENION, Cellenion is established as a trusted tool provider for leading research institutions.

Cell TherapyBiologicsDrug Delivery

Technology Platform

Precision microdispensing platform combining high-resolution imaging with non-contact picolitre dispensing for gentle isolation of single cells and 3D cellular models (spheroids, organoids). Core technology includes the cellenONE® and upcoming spheroONE® instruments, and the proteoCHIP® consumable line for single-cell proteomics.

Funding History

2
Total raised:$18.2M
Series A$15M
Seed$3.2M

Opportunities

The rapid growth of single-cell proteomics and the widespread adoption of 3D cell models (organoids/spheroids) in drug discovery present substantial market expansion opportunities.
Cellenion's open-platform strategy and proven installed base position it to become a standard tool for standardizing these complex, manual workflows in both academic and industrial labs.

Risk Factors

Key risks include competition in the single-cell analysis instrument space, potential slower-than-expected adoption of automated platforms over manual techniques, and execution risks associated with the successful launch and performance of the new spheroONE® system.
As a subsidiary, strategic dependency on parent company SCIENION is also a factor.

Competitive Landscape

Cellenion competes in the single-cell isolation and dispensing segment against companies like Berkeley Lights (now part of Bruker), Cytena (part of BICO), and On-chip Biotechnologies, as well as flow cytometry-based sorters. In the 3D model handling space, it faces emerging competition from specialized automation companies. Its differentiation lies in its open-platform flexibility, gentle piezo-dispensing technology, and integrated imaging for precise selection.